Results 1 to 10 of about 70,747 (277)

Active Pulmonary Tuberculosis Triggered by Interferon Beta-1b Therapy of Multiple Sclerosis: Four Case Reports and a Literature Review [PDF]

Medicina, 2020
In this paper, we reported on four cases of severe pulmonary active tuberculosis in patients with multiple sclerosis (MS) undergoing interferon beta-1b (IFNβ-1b) therapy. Disease-modifying therapies (DMTs) in MS may increase the risk of developing active
Carmen Adella Sirbu, Elena Dantes, Cristina Florentina Plesa, Any Docu Axelerad, Minerva Claudia Ghinescu   +4 more
doaj   +4 more sources

WITHDRAWN: Specific protein-protein interactions limit the cutaneous iontophoretic transport of interferon beta-1B and a poly-ARG interferon beta-1B analogue [PDF]

International Journal of Pharmaceutics: X, 2020
The first objective was to investigate the transdermal iontophoresis of interferon beta 1b (IFN); the second was to determine whether the addition of 10 Arg residues at the N-terminus, creating a highly charged poly-Arg analogue (Arg10-IFN), increased delivery.
S. Dubey, R. Perozzo, L. Scapozza, Y.N. Kalia   +3 more
doaj   +5 more sources

Interferon beta-1b for COVID-19. [PDF]

Lancet, 2020
Shalhoub S.
europepmc   +6 more sources

Multiple cutaneous necrotic lesions associated with Interferon beta-1b injection for multiple sclerosis treatment: A case report and literature review

Journal of Research in Pharmacy Practice, 2015
Multiple sclerosis (MS) is a chronic and debilitating inflammatory autoimmune disorder of the central nervous system. MS patients may experience severe local inflammatory skin reactions during disease-modifying therapy with subcutaneously injected ...
Gita Faghihi, Akram Basiri, Mohsen Pourazizi, Bahareh Abtahi-Naeini, Ali Saffaei   +4 more
doaj   +3 more sources

Pregnancy outcomes from the global pharmacovigilance database on interferon beta-1b exposure [PDF]

Therapeutic Advances in Neurological Disorders, 2020
Background: The goal of the present cohort study was to review outcomes of patients exposed to interferon beta-1b during pregnancy. Methods: Pregnancy cases with exposure to interferon beta-1b reported to Bayer’s pharmacovigilance (PV) database from ...
Kerstin Hellwig, Fernando Duarte Caron, Eva-Maria Wicklein, Aasia Bhatti, Alessandra Adamo   +4 more
doaj   +2 more sources

Pregnancy outcomes in patients exposed to interferon beta-1b. [PDF]

J Neurol Neurosurg Psychiatry, 2015
Romero RS, Lünzmann C, Bugge JP.
europepmc   +5 more sources

Randomized controlled open label trial on the use of favipiravir combined with inhaled interferon beta-1b in hospitalized patients with moderate to severe COVID-19 pneumonia [PDF]

International Journal of Infectious Diseases, 2021
Objective: To evaluate the therapeutic effectiveness of favipiravir combined with inhaled interferon beta-1b in adult patients hospitalized with moderate to severe COVID-19 pneumonia. Methods: A randomized, open-label controlled trial of oral favipiravir
Faryal Khamis, Hanan Al Naabi, Adil Al Lawati, Zaiyana Ambusaidi, Mariam Al Sharji, Umkulthum Al Barwani, Nenad Pandak, Zakariya Al Balushi, Maher Al Bahrani, Issa Al Salami, Ibrahim Al-Zakwani   +10 more
doaj   +2 more sources

Injectable interferon beta-1b for the treatment of relapsing forms of multiple sclerosis

Journal of Inflammation Research, 2010
Slobodan M JankovicPharmacology Department, Medical Faculty, University of Kragujevac, Kragujevac, SerbiaAbstract: Multiple sclerosis (MS) is chronic inflammatory and demyelinating disease with either a progressive (10%–15%) or relapsing ...
Slobodan M Jankovic
doaj   +4 more sources

Review of interferon beta-1b in the treatment of early and relapsing multiple sclerosis

Biologics: Targets & Therapy, 2009
Damiano Paolicelli, Vita Direnzo, Maria TrojanoDepartment of Neurological and Psychiatric Sciences, University of Bari, Bari, ItalyAbstract: Multiple sclerosis (MS) is the most common autoimmune illness of the central nervous system.
Damiano Paolicelli, Vita Direnzo, Maria Trojano   +2 more
doaj   +2 more sources

Type I interferon autoantibodies in hospitalized patients with Middle East respiratory syndrome and association with outcomes and treatment effect of interferon beta-1b in MIRACLE clinical trial. [PDF]

Influenza Other Respir Viruses, 2023
Alotaibi F, Alharbi NK, Rosen LB, Asiri AY, Assiri AM, Balkhy HH, Al Jeraisy M, Mandourah Y, AlJohani S, Al Harbi S, Jokhdar HAA, Deeb AM, Memish ZA, Jose J, Ghazal S, Al Faraj S, Al Mekhlafi GA, Sherbeeni NM, Elzein FE, AlMutairi BM, Al-Dawood A, Abdullah ML, Barhoumi T, Alenazi MW, Almasood A, Holland SM, Arabi YM, Saudi Critical Care Trials Group.   +27 more
europepmc   +3 more sources